130 related articles for article (PubMed ID: 30446803)
1. The impact of chronic myeloid leukemia on employment: the French prospective study.
De Barros S; Vayr F; Despas F; Strumia M; Podevin C; Gauthier M; Delabesse E; Soulat JM; Laurent G; Huguet F; Herin F
Ann Hematol; 2019 Mar; 98(3):615-623. PubMed ID: 30446803
[TBL] [Abstract][Full Text] [Related]
2. BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Cuellar S; Vozniak M; Rhodes J; Forcello N; Olszta D
J Oncol Pharm Pract; 2018 Sep; 24(6):433-452. PubMed ID: 28580869
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
Carneiro BA; Kaplan JB; Giles FJ
Expert Rev Hematol; 2015 Aug; 8(4):457-79. PubMed ID: 25938861
[TBL] [Abstract][Full Text] [Related]
4. Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Rea D
Ann Hematol; 2015 Apr; 94 Suppl 2():S149-58. PubMed ID: 25814081
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
Cornea MI; Levrat E; Pugin P; Betticher DC
J Med Case Rep; 2015 Apr; 9():30. PubMed ID: 26187587
[TBL] [Abstract][Full Text] [Related]
6. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
7. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
8. Bcr-Abl tyrosine kinase inhibitors: a patent review.
Desogus A; Schenone S; Brullo C; Tintori C; Musumeci F
Expert Opin Ther Pat; 2015 Apr; 25(4):397-412. PubMed ID: 25656651
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.
Radich JP; Mauro MJ
Hematol Oncol Clin North Am; 2017 Aug; 31(4):577-587. PubMed ID: 28673389
[TBL] [Abstract][Full Text] [Related]
10. Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy.
Massaro F; Colafigli G; Molica M; Breccia M
Expert Rev Hematol; 2018 Apr; 11(4):301-306. PubMed ID: 29522367
[TBL] [Abstract][Full Text] [Related]
11. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Gambacorti-Passerini C; Piazza R
JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia.
Ishida Y; Murai K; Yamaguchi K; Miyagishima T; Shindo M; Ogawa K; Nagashima T; Sato S; Watanabe R; Yamamoto S; Hirose T; Saitou S; Yonezumi M; Kondo T; Kato Y; Mochizuki N; Ohno K; Kishino S; Kubo K; Oyake T; Ito S;
Eur J Clin Pharmacol; 2016 Feb; 72(2):185-93. PubMed ID: 26507546
[TBL] [Abstract][Full Text] [Related]
13. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.
Zámečníkova A
Expert Rev Hematol; 2010 Feb; 3(1):45-56. PubMed ID: 21082933
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?
Eskazan AE; Ozmen D
Expert Rev Hematol; 2017 Jul; 10(7):583-586. PubMed ID: 28586242
[No Abstract] [Full Text] [Related]
15. [Therapeutic strategy for chronic myeloid leukemia: possibilities and prospects].
Turkina AG; Chelysheva EIu
Ter Arkh; 2013; 85(7):4-9. PubMed ID: 24137941
[TBL] [Abstract][Full Text] [Related]
16. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
17. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M
Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476
[TBL] [Abstract][Full Text] [Related]
18. Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.
Gugliotta G; Castagnetti F; Fogli M; Cavo M; Baccarani M; Rosti G
Expert Rev Hematol; 2013 Oct; 6(5):563-74. PubMed ID: 24083631
[TBL] [Abstract][Full Text] [Related]
19. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
20. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
